Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.64 |
| ▸ | LCK | P06239 | 2/20 | 0.60 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.60 |
| ▸ | CSF1R | P07333 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.60 |
| ▸ | RAF1 | P04049 | 6/20 | 0.53 |
| ▸ | BRAF | P15056 | 6/20 | 0.53 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4502525 | 0.83 | MAPK14 (0.53) | MAPK14RAF1BRAF | |
| SCHEMBL4501036 | 0.82 | BRAF (0.64) | MAPK14RAF1BRAF | |
| SCHEMBL14078239 | 0.78 | MAPK14 (0.65) | MAPK14LCKMAP2K1CSF1RKDR | |
| SCHEMBL4516090 | 0.78 | ALDH1A1 (0.47) | MAPK14LCKCSF1RKDRRAF1 | |
| SCHEMBL3528364 | 0.77 | MAPK14 (0.87) | MAPK14LCKMAP2K1CSF1RKDR | |
| SCHEMBL4502067 | 0.77 | MAPK14 (0.61) | MAPK14LCKCSF1RKDRRAF1 | |
| SCHEMBL14078303 | 0.77 | MAPK14 (0.86) | MAPK14LCKMAP2K1CSF1RKDR | |
| SCHEMBL5113219 | 0.77 | MAPK14 (1.00) | MAPK14LCKMAP2K1CSF1RKDR | |
| SCHEMBL14078286 | 0.76 | MAPK14 (0.77) | MAPK14LCKMAP2K1CSF1RKDR | |
| SCHEMBL5123367 | 0.76 | MAPK14 (0.68) | MAPK14LCKMAP2K1CSF1RKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286775-A1 | Bicyclic Derivatives as P38 Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2009-11-19 | — | — | US | claimed |
| CN-101208301-A | Bicyclic derivatives as p38 kinase inhibitors | PALAU PHARMA SA (ES) | 2008-06-25 | — | — | CN | claimed |
| EP-1917241-A2 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | Palau Pharma, S.A. (ES) | 2008-05-07 | — | — | EP | claimed |
| WO-2007000339-A1 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2007-01-04 | — | — | WO | claimed |
| US-20090286775-A1 | Bicyclic Derivatives as P38 Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2009-11-19 | — | — | US | disclosed |
| CN-101208301-A | Bicyclic derivatives as p38 kinase inhibitors | PALAU PHARMA SA (ES) | 2008-06-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286775-A1 | Bicyclic Derivatives as P38 Kinase Inhibitors | MAPK1, MAPKAPK2, MAPKAPK3 | MAPK14 26/4885LCK 173/4885MAP2K1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.